CXCL8 and neoplasm: Overexpression of EGFR plays a key role in HNSCC, supporting the use of cetuximab, a monoclonal anti‐EGFR antibody, as well as EGFR‐tyrosine kinase inhibitors (EGFR‐TKI), which inhibit tumor cell proliferation and the secretion of pro‐angiogenic factors by tumor cells, such as VEGF and IL‐8.